Cargando…

Biomarkers Predicting for Response and Relapse with Melanoma Systemic Therapy

Introduction of new systemic therapies in the last 10 years has radically improved outcomes for melanoma patients. Even so, not all patients benefit, so getting the right treatment to the right patient is a priority. These two major drug classes, small molecule targeted kinase inhibitors and immune...

Descripción completa

Detalles Bibliográficos
Autores principales: WELSH, Sarah J., CORRIE, Pippa G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society for Publication of Acta Dermato-Venereologica 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189745/
https://www.ncbi.nlm.nih.gov/pubmed/32346748
http://dx.doi.org/10.2340/00015555-3497